BRAF and neoplasm: To address whether BAY 87-2243-mediated complex I inhibition is efficient at reducing melanoma tumor growth in vivo, we tested the inhibitor in four BRAF mutant melanoma xenograft models using G-361, SK-MEL-28, A-375, and LOX-IMVI cancer cells.